{"product_id":"alpesib-150mg-tablet-alpelisib","title":"Alpesib 150mg tablet (alpelisib)","description":"\u003cp\u003e\u003cstrong\u003eAlpesib 150 mg\u003c\/strong\u003e\u003cspan\u003e is an oral targeted anticancer medicine manufactured by \u003c\/span\u003e\u003cstrong\u003eEverest Pharmaceuticals Ltd., Bangladesh\u003c\/strong\u003e\u003cspan\u003e. Each film-coated tablet contains \u003c\/span\u003e\u003cstrong\u003eAlpelisib 150 mg\u003c\/strong\u003e\u003cspan\u003e, a selective phosphatidylinositol-3-kinase (PI3K) inhibitor with predominant activity against PI3K-alpha. It is used in combination with \u003c\/span\u003e\u003cstrong\u003efulvestrant\u003c\/strong\u003e\u003cspan\u003e for the treatment of postmenopausal women and men with hormone receptor-positive (HR+), HER2-negative, \u003c\/span\u003e\u003cstrong\u003ePIK3CA-mutated advanced or metastatic breast cancer\u003c\/strong\u003e\u003cspan\u003e following progression on or after endocrine-based therapy. Alpelisib works by inhibiting abnormal PI3K\/AKT signaling associated with PIK3CA mutations, helping to slow the growth of cancer cells. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe recommended dose is \u003cstrong\u003e300 mg once daily with food\u003c\/strong\u003e, which corresponds to two 150 mg tablets, although dose reductions may be required depending on tolerability and adverse reactions. Important treatment-related risks include \u003cstrong\u003ehyperglycemia, diarrhea, rash, and pneumonitis\u003c\/strong\u003e, so treatment requires appropriate medical monitoring.\u003c\/span\u003e\u003c\/p\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":45104551362603,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/Alpesib.jpg?v=1787575705","url":"https:\/\/xomeds.com\/ru\/products\/alpesib-150mg-tablet-alpelisib","provider":"XOMEDS","version":"1.0","type":"link"}